Beijing, Shanghai & Boston, Jun. 8, 2023 — Jacobio Pharma (1167.HK) has received IND (Investigational New Drug) approval of its self-developed drug JAB-26766 (PARP7 inhibitor) from the Center for Drug Evaluation (CDE) of China. Jacobio plans to initiate a Phase I/IIa advanced solid tumors clinical trial in the China.
PARP7 inhibitors target I/O (immuno-oncology) signaling pathway and can be used to treat various solid tumors such as squamous NSCLC, and HNSCC. Studies show that, PARP7 inhibitors have the potential to directly inhibit tumor growth and enhance the anti-tumor immune response. JAB-26766 is an orally administered small-molecule with significant antitumor activity against a variety of tumor models in mice.
PARP7 is located downstream of STING signaling pathway, and JAB-26766 has potential to combine with Jacobio’s self-developed CD73 STING-iADC. JAB-26766 also has the potential to be used in combination with PD-(L)1 monoclonal antibodies to bring more treatment options to patients.
Jacobio is committed to developing global first-in-class drugs, and key programs are targeting among the top three worldwide. Currently there is only one PARP7 inhibitor in the Phase I clinical stage globally.
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.